Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 6, 2024
Distillery Therapeutics

NR4A1 activation for UTIs

BioCentury | Feb 28, 2019
Preclinical News

Removing genes from CAR Ts to improve efficacy, safety

BioCentury | Jan 25, 2018
Translation in Brief

Melanoma vs. melanoma

PEDF-presenting exosomes may be able to prevent metastasis of melanoma
BioCentury | Oct 30, 2008
Cover Story

BCL-2 double take

BioCentury | May 23, 2007
Clinical News

Researchers link NR4A1, NR4A3 to AML

Items per page:
1 - 9 of 9